Agilon Health (NYSE:AGL) Price Target Raised to $170.00

Agilon Health (NYSE:AGL) had its price target hoisted by equities research analysts at Wells Fargo & Company from $146.00 to $170.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 55.11% from the company’s current price.

A number of other research analysts have also recently issued reports on the stock. Sanford C. Bernstein raised shares of Agilon Health from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $86.00 to $125.00 in a research report on Tuesday, September 15th. Robert W. Baird set a $116.00 price objective on shares of Agilon Health in a report on Thursday, August 6th. Truist Financial set a $112.00 target price on shares of Agilon Health and gave the company a “hold” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a research note on Monday, August 24th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Agilon Health from $31.00 to $85.00 and gave the company an “underweight” rating in a report on Monday, August 24th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $107.38.

Agilon Health Stock Down 0.6%

AGL stock traded down $0.70 during midday trading on Friday, hitting $109.60. The stock had a trading volume of 26,961 shares, compared to its average volume of 316,635. The business has a 50-day moving average of $90.11 and a two-hundred day moving average of $68.51. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.13 and a quick ratio of 1.13. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -19.75 and a beta of 3.10. Agilon Health has a 52-week low of $7.48 and a 52-week high of $133.04.

Agilon Health (NYSE:AGL) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $1.97 EPS for the quarter, beating the consensus estimate of ($1.23) by $3.20. Agilon Health had a negative return on equity of 51.97% and a negative net margin of 1.45%. The business had revenue of $1.52 billion during the quarter, compared to analyst estimates of $1.46 billion. As a group, equities research analysts forecast that Agilon Health will post -2.90 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agilon Health

Large investors have recently modified their holdings of the stock. Sterling Capital Management LLC bought a new position in Agilon Health in the 3rd quarter worth about $33,000. Root Financial Partners LLC bought a new stake in Agilon Health during the 3rd quarter valued at about $57,000. State of Alaska Department of Revenue purchased a new position in Agilon Health in the third quarter worth about $64,000. Allworth Financial LP purchased a new position in Agilon Health in the second quarter worth about $114,000. Finally, Proficio Capital Partners LLC bought a new position in shares of Agilon Health in the second quarter worth approximately $210,000.

About Agilon Health

Agilon Health is a U.S. healthcare company that partners with primary care physicians to provide care for patients enrolled in Medicare Advantage plans. Its model is designed to help physician groups move from traditional fee-for-service care toward value-based care, in which providers are rewarded for improving patients’ health and coordinating their care. The company provides participating physician groups with clinical, operational, technology and administrative support, along with resources to manage patient populations and coordinate care across local healthcare networks.